BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 7528120)

  • 21. Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3.
    Thor A; Gorstein F; Ohuchi N; Szpak CA; Johnston WW; Schlom J
    J Natl Cancer Inst; 1986 Jun; 76(6):995-1006. PubMed ID: 3520078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate-derived Ets factor is overexpressed in serous epithelial ovarian tumors.
    Rodabaugh KJ; Mhawech-Fauceglia P; Groth J; Lele S; Sood AK
    Int J Gynecol Pathol; 2007 Jan; 26(1):10-5. PubMed ID: 17197890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunoperoxidase localization of a high-molecular-weight mucin recognized by monoclonal antibody 1D3.
    Gangopadhyay A; Bhattacharya M; Chatterjee SK; Barlow JJ; Tsukada Y
    Cancer Res; 1985 Apr; 45(4):1744-52. PubMed ID: 3884144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CA 125 in ovarian cysts, serous effusions and peritoneal washings: immunocytochemical expression.
    Carico E; Chicchirichi R; Atlante M; Giovagnoli M; Vecchione A
    Anticancer Res; 1995; 15(2):631-4. PubMed ID: 7763049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The value of epithelial membrane antigen in the diagnosis of ovarian tumors.
    Fujimoto I; Hirai Y; Hasumi K; Masubuchi K; Osamura Y
    Acta Cytol; 1990; 34(4):549-54. PubMed ID: 1695804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Borderline ovarian tumors].
    Ivanov S
    Akush Ginekol (Sofiia); 2002; 42(1):23-5. PubMed ID: 11935694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance.
    Garzetti GG; Ciavattini A; Goteri G; De Nictolis M; Stramazzotti D; Lucarini G; Biagini G
    Gynecol Oncol; 1995 Feb; 56(2):169-74. PubMed ID: 7896180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of Fas and FasL in human serous ovarian epithelial tumors.
    van Haaften-Day C; Russell P; Davies S; King NJ; Tattersall MH
    Hum Pathol; 2003 Jan; 34(1):74-9. PubMed ID: 12605369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas.
    Friedman EL; Hayes DF; Kufe DW
    Cancer Res; 1986 Oct; 46(10):5189-94. PubMed ID: 3530435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor associated antigen in ovarian carcinoma.
    Negishi Y; Mutai Y; Akiya K; Fujiwara Y; Singh G
    Nihon Sanka Fujinka Gakkai Zasshi; 1984 Jan; 36(1):126-32. PubMed ID: 6199439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Mucin histochemical and immunohistochemical studies of mucinous ovarian tumors].
    Shi ZL
    Zhonghua Bing Li Xue Za Zhi; 1989 Sep; 18(3):201-3. PubMed ID: 2636063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generation of monoclonal antibodies reacting with human epithelial ovarian cancer.
    Tagliabue E; Mènard S; Della Torre G; Barbanti P; Mariani-Costantini R; Porro G; Colnaghi MI
    Cancer Res; 1985 Jan; 45(1):379-85. PubMed ID: 3965146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical factors and biomarkers in ovarian tumors development.
    Vrabie CD; Petrescu A; Waller M; Dina I
    Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
    Shibata K; Kajiyama H; Mizokami Y; Ino K; Nomura S; Mizutani S; Terauchi M; Kikkawa F
    Gynecol Oncol; 2005 Jul; 98(1):11-8. PubMed ID: 15907336
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical evaluation of sialosyl-Tn antigens in various ovarian carcinomas.
    Ryuko K; Iwanari O; Kitao M; Moriwaki S
    Gynecol Oncol; 1993 May; 49(2):215-24. PubMed ID: 8504990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Telomerase activity is a useful marker to distinguish malignant pancreatic cystic tumors from benign neoplasms and pseudocysts.
    Yeh TS; Cheng AJ; Chen TC; Jan YY; Hwang TL; Jeng LB; Chen MF; Wang TC
    J Surg Res; 1999 Dec; 87(2):171-7. PubMed ID: 10600346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of extracellular matrix proteins in ovarian serous tumors.
    Salani R; Neuberger I; Kurman RJ; Bristow RE; Chang HW; Wang TL; Shih IeM
    Int J Gynecol Pathol; 2007 Apr; 26(2):141-6. PubMed ID: 17413980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal antibody, Mab 12C3, is a sensitive immunohistochemical marker of early malignant change in epithelial ovarian tumors.
    Yamada K; Ohkawa K; Joh K
    Am J Clin Pathol; 1995 Mar; 103(3):288-94. PubMed ID: 7872250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
    Brustmann H
    Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.